Journal
GASTROENTEROLOGY
Volume 151, Issue 2, Pages 267-270Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2016.04.034
Keywords
Genetic; Biomarker; Prognostic Factor; Diagnostic; IPMN; PDAC
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG) [K.L. 2544/1-1, K.L. 2544/1-2]
- Forschungskern SyStaR
- BIU (Bohringer Ingelheim Ulm)
- Else-Kroner-Fresenius-Stiftung [2011_A200]
- German Cancer Aid Max Eder Fellowship
- German Cancer Aid Grant [111879]
- Fritz-Thyssen Foundation [2015-00363]
- Hector Foundation Cancer Research Fund
- Baden-Wurttemberg Stiftung
- Interdisciplinary Center for Clinical Research (IZKF Aachen), RWTH Aachen University Medical School, Aachen, Germany
- BMBF [01GS08114, 01ZX1305C, 01KT1506]
- Heidelberger Stiftung Chirurgie
- Biomaterial Bank Heidelberg (BMBF) [01EY1101]
Ask authors/readers for more resources
Intraductal papillary mucinous neoplasms (IPMNs) are the most frequent cystic pancreatic tumors. Little is known about their molecular alterations, but mutations in GNAS have been reported to promote IPMN formation. A tumor-derived fraction of circulating cell-free DNA (cfDNA), isolated from blood samples, contains many of the same mutations as the primary tumor, and could be a tool for noninvasive disease monitoring. We found that the total amount of cfDNA can discriminate between individuals without pancreatic lesions (controls) and patients with Fukuoka-negative branch-duct IPMN or pancreatic cancer. Furthermore, we detected GNAS mutations in cfDNA from patients with IPMN, but not in patients with serous cystadenoma or controls. Analyses of cfDNA might therefore be used in the diagnosis of patients with IPMN or in monitoring disease progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available